Novartis Gene Therapies, Inc.

Novartis Gene Therapies, Inc.

Novartis Gene Therapies, Inc.

Overview
Date Founded

2010

Headquarters

2275 Half Day Road,Suite 300,Bannockburn, IL 60015

Type of Company

Private

Employees (Worldwide)

18

Industries

Biotechnology
Medical Support Services
Hospitals & Patient Services

Company Description

Novartis Gene Therapies, Inc. develops gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and is headquartered in Bannockburn, IL.

Contact Data
Trying to get in touch with decision makers at Novartis Gene Therapies, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Scientific Officer & Senior Vice President, Research & Development

Senior Vice President & Chief Human Resources Officer

Senior Vice President, Chief Medical Officer

Senior Vice President, Chief Regulatory & Quality Officer

Vice President, Business Operations

President

Senior Director

Senior Director

Chief Business Officer & Senior Vice President

Associate Marketing Manager

Paths to Novartis Gene Therapies, Inc.
Potential Connections via
Relationship Science
You
Novartis Gene Therapies, Inc.
Recent Transactions
Details Hidden

Novartis AG, Novartis Gene Therapies, Inc. purchase Astrazeneca Plc /Longmont Manufacturing Operations from AstraZeneca Plc

Details Hidden

Novartis International AG, Novartis AG purchase Novartis Gene Therapies, Inc.

Details Hidden

Novartis Gene Therapies, Inc. issued USD Common Stock

Transaction Advisors
Investment Advisor

Advised onNovartis International AG, Novartis AG purchase Novartis Gene Therapies, Inc.

Escrow Agent

Advised onNovartis Gene Therapies, Inc. issued USD Common Stock

Underwriter

Advised onNovartis Gene Therapies, Inc. issued USD Common Stock

Legal Advisor

Advised onNovartis Gene Therapies, Inc. issued USD Common Stock

Legal Advisor

Advised onNovartis Gene Therapies, Inc. issued USD Common Stock

Legal Advisor

Advised onNovartis Gene Therapies, Inc. issued USD Common Stock

Advisors & Consultants
Publicist

Associate Director at The W2O Group

Key Stats and Financials As of
Market Capitalization
$7.83B
Total Enterprise Value
Earnings Per Share
Investors
Details Hidden

Boxer Capital LLC invests in public and private companies located in the US. They target companies operating in the fields of biotech. They provide financing for early stage capital requirements.

Details Hidden

RTW Investments invests in companies located in the US. The firm targets companies operating in the fields of medtech and biopharma. It provides financing for early stage capital requirements.

Details Hidden

CWI employs a long-term, value-oriented global investment approach and a multiple portfolio manager system that combines teamwork and individual accountability. The firm utilizes fundamental research to gather in-depth information on markets and companies around the world. They also employ a security-by-security approach to portfolio construction and emphasize long-term investments. Their strategies focus on determining the difference between the fundamental value of a company and its price in the marketplace. CWI offers a wide variety of equity, fixed-income and balanced investment strategies. Their strategies are categorized as global, multi-regional and regional investment strategies.

Suppliers
REGENXBIO, Inc. Biotechnology | Rockville, MD

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Nationwide Children's Hospital is a nationally ranked pediatric acute care teaching hospital located in the Southern Orchards neighborhood of Columbus, Ohio. The hospital has 673 pediatric beds and is affiliated with the Ohio State University College of Medicine.

Asklepios BioPharmaceutical, Inc. Hospitals & Patient Services | Research Triangle Park, NC

Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC.

Competitors
Biogen, Inc. Biotechnology - Cambridge, MA

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Cytokinetics, Inc. Pharmaceuticals - South San Francisco, California

Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Novartis Gene Therapies, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Novartis Gene Therapies, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Novartis Gene Therapies, Inc..